SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

(2021) Emma S. Winkler et al.   CELL

High‐throughput detection of antibodies targeting the SARS‐CoV ‐2 Spike in longitudinal convalescent plasma samples

(2021) Sai Priya Anand et al.   TRANSFUSION

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

(2021) Romain Gasser et al.   Cell Reports

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

(2021) Leonidas Stamatatos et al.   SCIENCE

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

(2021) Alexandra Tauzin et al.   Cell Host & Microbe

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

(2021) Irfan Ullah et al.   IMMUNITY

Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2

(2021) Jérémie Prévost et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A government-led effort to identify correlates of protection for COVID-19 vaccines

(2021) Richard A. Koup et al.   NATURE MEDICINE

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

(2021) Madeleine F. Jennewein et al.   Cell Reports

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

(2021) Alexandra Tauzin et al.   Cell Host & Microbe

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

(2021) Alice Cho et al.   NATURE

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

(2021) Rishi R. Goel et al.   SCIENCE

Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern

(2021) Wenwei Li et al.   Cell Reports

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

(2020) Hong Zhou et al.   CURRENT BIOLOGY

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

(2020) Javier A. Jaimes et al.   JOURNAL OF MOLECULAR BIOLOGY

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

(2020) Fabian Schmidt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

(2020) Guillaume Beaudoin-Bussières et al.   mBio

Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

(2020) Suzanne Pickering et al.   PLoS Pathogens

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

(2020) Jeffrey Seow et al.   Nature Microbiology

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

(2020) Josée Perreault et al.   BLOOD

Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide

(2009) I. G. Madu et al.   JOURNAL OF VIROLOGY